Research Paper Volume 14, Issue 17 pp 7170—7185

A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma


Figure 1. Establishment of a circadian rhythm- (CR-) related gene signature in prostate adenocarcinoma (PRAD). (A) Enrichment score (ES) of CR-related gene set was significantly enriched in normal tissue than tumor tissue. (B) High-ES patients had an improved relapse-free survival (RFS) than their counterparts. (C) CR-related gene set was positively enriched in normal tissue compared with tumor tissue. (D) 13 CR-related genes were qualified in univariate Cox regression analysis (FBXL22, FBXL6, MTA1, NR2F6, TP53, BTRC, GHRL, RORC, CIPC, DRD4, MTOR, PPARGC1A, ZFHX3; P<0.05). (E, F) 13 qualified genes were further filtered using LASSO regression analysis to eliminate multicollinearity and seven eligible genes (FBXL22, MTA1, TP53, RORC, DRD4, PPARGC1A, ZFHX3) were eventually acquired for establishment of a CR-related gene signature for predicting RFS in PRAD patients.